Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOXIRI vs mFOLFOX6 + Bevacizumab in RAS Mutant Colorectal Liver Metastases
NCT04781270Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Conversion Resection Rate at 6 months. Started Apr 2021; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04781270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781270.